latest news releases from the newsroom
Brodsky & Smith, LLC
Law Offices of Brodsky & Smith, LLC Announces Class Action Lawsuit Against Aerosonic Corporation -- AIM
BALA CYNWYD, Pa., Nov. 25, 2003 (PRIMEZONE) -- Law offices of Brodsky & Smith, LLC today announces that a securities class action lawsuit has been filed on behalf of shareholders who purchased the common stock and other securities of Aerosonic Corporation ("Aerosonic or the "Company") (AMEX:AIM), between May 3, 1999 and March 17, 2003, inclusive (the "Class Period"). The class action lawsuit was filed in the United States District Court for the Middle District of Florida against Aerosonic and certain of its officers and/or directors.
Moore-Handley, Inc. Reports Results of Operations for the Quarter Ended September 30, 2003
BIRMINGHAM, Ala., Nov. 25, 2003 (PRIMEZONE) -- Moore-Handley, Inc. (Pink Sheets:MHCO), a Birmingham-based distributor of hardware and home center products, reported net income of $28,000 or $0.02 per diluted share for the quarter ended September 30, 2003 vs. $53,000 or $0.03 per diluted share for the same period in 2002. The quarter ended September 30, 2003 included a charge to income, net of taxes, of $29,000 or $0.02 per diluted share because of a change in the allowance for uncollectible vendor receivables. For the nine months ended September 30, 2003 this charge, net of taxes, was $256,000 or $0.14 per diluted share.
Atlas Minerals Inc.
Atlas Announces Third Quarter Financial Results
DENVER, Nov. 25, 2003 (PRIMEZONE) -- Atlas Minerals Inc. (OTCBB:ATMR) (the "Company") announced today its financial results for the nine months ended September 30, 2003. As of September 30, 2003 the Company had a working capital deficit of $84,000 and a cash balance of $12,000. The Company reports total assets of $700,000 and total liabilities of $450,000.
ViroPharma and Schering-Plough Enter Into Agreement For New Intranasal Formulation of Pleconaril
EXTON, Pa. and KENILWORTH, N.J., Nov. 25, 2003 (PRIMEZONE) -- ViroPharma Incorporated (Nasdaq:VPHM) and Schering-Plough Corporation (NYSE:SGP) today announced that the companies have entered into an option agreement to license ViroPharma's intranasal formulation of the antiviral compound pleconaril to Schering-Plough for the treatment of the common cold in the United States and Canada. The new intranasal formulation of pleconaril represents an optimized delivery approach for this compound.
Press Release from Skandia's Board
STOCKHOLM, Sweden, Nov. 25, 2003 (PRIMEZONE) -- Following the Annual General Meeting, Skandia's Board decided on May 6, 2003 to commission Attorney Otto Rydbeck and Authorized Public Accountant Goran Tidstrom to investigate certain areas of Skandia's operations. The assignment was to include transactions between Skandia and Skandia Liv, the principles of the embedded value method and the processes related to compensation and incentive programs.